Which clinical trials provide evidence supporting the use of olaparib (Lynparza) in ovarian cancer?

Clinical Trials Supporting Olaparib in Ovarian Cancer

Multiple landmark phase III trials have established olaparib's efficacy across different ovarian cancer settings, with the strongest evidence in BRCA-mutated disease showing substantial progression-free survival benefits and emerging overall survival advantages.

First-Line Maintenance Setting

SOLO-1 Trial: BRCA-Mutated Newly Diagnosed Disease

The SOLO-1 trial demonstrated the most dramatic benefit for olaparib, with a 70% reduction in disease progression or death risk in BRCA-mutated advanced ovarian cancer following first-line platinum-based chemotherapy 1, 2.

• Primary endpoint: Investigator-assessed progression-free survival (PFS) showed hazard ratio (HR) 0.30 (95% CI: 0.23-0.41, P<0.0001) 1, 2
• Clinical impact: 60% of patients remained progression-free at 3 years with olaparib versus only 27% with placebo 2
• Median PFS: Not reached with olaparib versus 13.8 months with placebo after 41 months median follow-up 3, 2
• Patient population: 391 patients with germline or somatic BRCA mutations, 82% in complete response to platinum-based chemotherapy 3
• Dosing: Olaparib 300 mg orally twice daily for up to 2 years 3

PAOLA-1 Trial: HRD-Positive Disease with Bevacizumab

The PAOLA-1 trial established olaparib combined with bevacizumab for HRD-positive newly diagnosed advanced ovarian cancer 1, 3.

• PFS benefit in HRD-positive patients: HR 0.33 (95% CI: 0.25-0.45), with median PFS of 37.2 months versus 17.7 months with placebo/bevacizumab 3
• Overall survival benefit: Median OS 75.2 months versus 57.3 months (HR 0.62; 95% CI: 0.45-0.85) in HRD-positive subgroup 3
• Critical caveat: Patients with HRD-negative tumors showed no benefit (PFS HR 1.00; OS HR 1.18), indicating biomarker testing is essential 3
• Patient characteristics: 48% had HRD-positive tumors; 62% had BRCA mutations within the HRD-positive cohort 3
• Second PFS analysis: Continued benefit beyond first progression with PFS2 of 36.5 versus 32.6 months (HR 0.78, P=0.0125) 4

Recurrent Disease Maintenance Setting

SOLO-2 Trial: BRCA-Mutated Platinum-Sensitive Relapse

SOLO-2 demonstrated both progression-free and overall survival benefits in BRCA-mutated platinum-sensitive recurrent ovarian cancer 1.

• PFS benefit: HR 0.30 (95% CI: 0.22-0.41, P<0.0001), with median PFS of 19.1 versus 5.5 months 1, 3
• Overall survival: Final analysis showed median OS of 51.7 versus 38.8 months (HR 0.74; 95% CI: 0.54-1.00; P=0.054), representing a 12.9-month improvement despite not reaching statistical significance 3, 5
• Patient population: 295 patients with germline BRCA mutations who had received ≥2 prior platinum regimens and were in response to most recent platinum therapy 3
• Long-term follow-up: Median follow-up of 65.7 months confirmed sustained benefit 5

Study 19: Broader Population Including BRCA Wild-Type

Study 19 was the first maintenance trial demonstrating olaparib benefit in platinum-sensitive recurrent disease, including patients without BRCA mutations 1.

• Overall PFS: Median 8.4 versus 4.8 months (HR 0.35; 95% CI: 0.25-0.49, P<0.001) 1
• BRCA-mutated subgroup: 11.2 versus 4.3 months median PFS 1
• BRCA wild-type subgroup: 7.4 versus 5.5 months (HR 0.54; 95% CI: 0.34-0.85, P=0.0075), showing benefit but less robust than BRCA-mutated patients 1
• Overall survival: 29.8 versus 27.8 months in intention-to-treat population after 78 months follow-up 1

Treatment Setting for Recurrent Disease

SOLO-3 Trial: Treatment Versus Chemotherapy

SOLO-3 compared olaparib directly to single-agent chemotherapy in platinum-sensitive relapsed BRCA-mutated ovarian cancer, showing superior response rates and PFS 1.

• Objective response rate: 72% with olaparib versus 51% with chemotherapy (odds ratio 2.53; 95% CI: 1.40-4.58, P=0.002) 1
• PFS by independent review: HR 0.62 (95% CI: 0.43-0.91, P=0.013), median 13.4 versus 9.2 months 1
• Overall survival caveat: Final OS analysis showed no benefit overall (HR 1.07), with favorable results only in patients with 2 prior lines (HR 0.83) but potential detriment in ≥3 prior lines (HR 1.33) 6
• BRCA reversion mutations: Only 3.5% of patients had detectable BRCA reversion mutations at baseline, but none achieved objective response, highlighting resistance mechanism 6

LIGHT Study: Treatment by HRD Status

The LIGHT study prospectively evaluated olaparib treatment efficacy across biomarker-defined cohorts 7.

• 18-month OS rates: 86.4% (germline BRCA), 88.0% (somatic BRCA), 78.6% (HRD-positive non-BRCA), and 59.6% (HRD-negative) 7
• Long-term treatment: 31% of patients with germline or somatic BRCA mutations remained on treatment >18 months 7
• Biomarker importance: Demonstrates clear hierarchy of benefit: BRCA-mutated > HRD-positive non-BRCA > HRD-negative 7

Guideline Recommendations

ASCO guidelines provide strong, evidence-based recommendations for olaparib use across multiple ovarian cancer settings 1.

Maintenance Therapy Recommendations:

• First-line maintenance: Olaparib 300 mg twice daily for BRCA-mutated advanced epithelial ovarian cancer (strong recommendation, high-quality evidence) 1
• Recurrent disease maintenance: Olaparib 300 mg twice daily for patients responding to platinum-based therapy, regardless of BRCA status, though benefit is greatest in BRCA-mutated disease (strong recommendation, high-quality evidence) 1
• HRD-positive tumors: Olaparib recommended for patients with genomic instability determined by Myriad myChoice CDx who have not recurred within 6 months of platinum therapy (strong recommendation, high-quality evidence) 1

Treatment Setting Recommendations:

• Recurrent disease treatment: Olaparib approved for germline BRCA-mutated ovarian cancer after ≥3 prior chemotherapy lines 1, 3
• Treatment duration: Continue until disease progression or unacceptable toxicity 1, 3

Real-World Evidence

A Chinese single-center study confirmed olaparib's effectiveness in real-world practice 8:

• 24-month PFS rates: 60.4% in first-line maintenance and 45.7% in platinum-sensitive recurrent maintenance settings 8
• BRCA-mutated patients: 24-month PFS of 72.7% in recurrent maintenance setting 8
• Safety profile: Consistent with clinical trials, with no new safety signals except skin pigmentation 8

Key Clinical Considerations

Biomarker testing is absolutely essential before initiating olaparib therapy, as benefit correlates directly with BRCA mutation and HRD status 1, 3, 7.

• Testing hierarchy: Germline BRCA testing first, followed by somatic BRCA and HRD testing if germline negative 1, 7
• HRD testing: Use validated assays (Myriad myChoice CDx) with genomic instability score ≥42 defining HRD-positive status 3, 7
• Line of therapy matters: Greatest benefit in earlier lines of therapy; consider potential diminishing returns after multiple prior regimens 6
• BRCA reversion mutations: May confer resistance; consider testing at progression if initially BRCA-mutated 6